Cargando…

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

KRAS G12C mutations are critical in the pathogenesis of multiple cancer types, including non-small cell lung (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal (CRC) cancers. As such, they have increasingly become a target of novel therapies in the management of these malignancies. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qunaj, Lindor, May, Michael S., Neugut, Alfred I., Herzberg, Benjamin O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543081/ https://www.ncbi.nlm.nih.gov/pubmed/37790760 http://dx.doi.org/10.3389/fonc.2023.1252516

Ejemplares similares

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Targeting KRAS G12C mutations in colorectal cancer
por: Zhao, Ming-He, et al.
Publicado: (2022)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C)
por: Zhuang, Haiming, et al.
Publicado: (2022)

Serum-Based KRAS(G12/G13) Mutation Detection Using Droplet Digital PCR: Clinical Implications and Limitations in Colorectal Adenocarcinoma With Tumor Heterogeneity
por: Kim, Ju Seok, et al.
Publicado: (2021)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

Non-genetic adaptive resistance to KRAS(G12C) inhibition: EMT is not the only culprit
por: Ning, Wenjuan, et al.
Publicado: (2022)

Targeting KRAS(G12C)-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
por: Ji, Jingran, et al.
Publicado: (2022)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
por: Wang, Jianlei, et al.
Publicado: (2022)

Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
por: Jiao, Delong, et al.
Publicado: (2020)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
por: Bannoura, Sahar F., et al.
Publicado: (2022)

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023)

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
por: Pirlog, Radu, et al.
Publicado: (2022)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2023)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era
por: Ciardiello, D., et al.
Publicado: (2022)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
por: Arrington, Amanda K., et al.
Publicado: (2012)

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
por: Koulouridi, Asimina, et al.
Publicado: (2022)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients
por: Fu, Xin-Hui, et al.
Publicado: (2019)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
por: Salem, Mohamed E., et al.
Publicado: (2022)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_csi80jlgumgo89s6dffsj3qkq5